InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Contineum Therapeutics, Inc.

CTNM Clue Score32
United States Fiscal year ends December CIK 0001855175
$13.38 +1.52% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $13.38 +10.03% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 5 Apr 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2023Revenue50.0Operating income16.1Net income22.7EPS, diluted0.08Fiscal year 2024Revenue0.0 −100.0%Operating income−50.9Net income−42.3 −286.0%EPS, diluted−2.18Fiscal year 2025Operating income−68.1Net income−60.0EPS, diluted−2.17
FY2023FY2024FY2025
Revenue 50.0 0.0 n/a
Growth −100.0%
Operating income 16.1 −50.9 −68.1
Net income 22.7 −42.3 −60.0
Growth −286.0%
EPS, diluted 0.08 −2.18 −2.17

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2023Operating margin32.2%Net margin45.4%Free cash flow margin37.9%Fiscal year 2024Fiscal year 2025
FY2023FY2024FY2025
Operating margin 32.2% n/a n/a
Net margin 45.4% n/a n/a
Free cash flow margin 37.9% n/a n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow19.3Capital expenditure−0.4Free cash flow18.9Fiscal year 2024Operating cash flow−32.8Capital expenditure−0.5Free cash flow−33.4 −276.2%Fiscal year 2025Operating cash flow−55.3Capital expenditure−0.2Free cash flow−55.5
FY2023FY2024FY2025
Operating cash flow 19.3 −32.8 −55.3
Capital expenditure −0.4 −0.5 −0.2
Free cash flow 18.9 −33.4 −55.5
Growth −276.2%

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Cash15.5Shareholders’ equity−67.9Fiscal year 2024Cash21.9Shareholders’ equity198.1Fiscal year 2025Cash75.6Shareholders’ equity261.0
FY2023FY2024FY2025
Cash 15.5 21.9 75.6
Shareholders’ equity −67.9 198.1 261.0

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024† 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
50.0 0.0 n/a
Growth −100.0%
27.6 38.4 51.5
6.3 12.5 16.5
16.1 −50.9 −68.1
Growth −416.6%
23.2 −42.3 −60.1
0.5 0.0 0.0
22.7 −42.3 −60.0
Growth −286.0%
Per share
1.36 −2.18 −2.17
0.08 −2.18 −2.17
Growth −2,825.0%
2.3 19.4 27.7
3.4 19.4 27.7
Growth +470.0% +43.1%

† The diluted share count jumps at 2024, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 2 of 3 years on file.